Repurposing bacterial toxins for intracellular delivery of therapeutic proteins

被引:41
作者
Beilhartz, Greg L. [1 ]
Sugiman-Marangos, Seiji N. [1 ]
Melnyk, Roman A. [1 ,2 ]
机构
[1] Hosp Sick Children Res Inst, Mol Med Program, 686 Bay St, Toronto, ON M5G 0A4, Canada
[2] Univ Toronto, Dept Biochem, 1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada
基金
加拿大健康研究院;
关键词
Bacterial toxins; Intracellular protein delivery; Biologics; Protein therapeutics; Diphtheria toxin; VIRUS-LIKE PARTICLES; BLOOD-BRAIN-BARRIER; GLIOBLASTOMA-MULTIFORME CELLS; BINDING DOMAIN SUBSTITUTION; ANTHRAX PROTECTIVE ANTIGEN; FACTOR FUSION PROTEIN; DIPHTHERIA-TOXIN; DRUG-DELIVERY; MAMMALIAN-CELLS; RECOMBINANT IMMUNOTOXIN;
D O I
10.1016/j.bcp.2017.04.009
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Despite enormous efforts, achieving efficacious levels of proteins inside mammalian cells remains one of the greatest challenges in biologics-based drug discovery and development. The inability of proteins to readily cross biological membranes precludes access to the wealth of intracellular targets and applications that lie within mammalian cells. Existing methods of delivery commonly suffer from an inability to target specific cells and tissues, poor endosomal escape, and limited in vivo efficacy. The aim of the present commentary is to highlight the potential of certain classes of bacterial toxins, which naturally deliver a large protein into the cytosolic compartment of target cells after binding a host cell-surface receptor with high affinity, as robust protein delivery platforms. We review the progress made in recent years toward demonstrating the utility of these systems at delivering a wide variety of protein cargo, with special attention paid to three distinct toxin-based platforms. We contend that with recent advances in protein deimmunization strategies, bacterial toxins are poised to introduce biologics into the inner sanctum of cells and treat a wealth of heretofore untreatable diseases with a new generation of therapeutics. (C) 2017 Elsevier Inc. All rights reserved.
引用
收藏
页码:13 / 20
页数:8
相关论文
共 95 条
[41]   DIPHTHERIA-TOXIN RECEPTOR-BINDING DOMAIN SUBSTITUTION WITH INTERLEUKIN-6 - GENETIC CONSTRUCTION AND INTERLEUKIN-6 RECEPTOR-SPECIFIC ACTION OF A DIPHTHERIA TOXIN-RELATED INTERLEUKIN-6 FUSION PROTEIN [J].
JEAN, LFL ;
MURPHY, JR .
PROTEIN ENGINEERING, 1991, 4 (08) :989-994
[42]   Atomic structure of anthrax protective antigen pore elucidates toxin translocation [J].
Jiang, Jiansen ;
Pentelute, Bradley L. ;
Collier, R. John ;
Zhou, Z. Hong .
NATURE, 2015, 521 (7553) :545-U323
[43]   Protein delivery using engineered virus-like particles [J].
Kaczmarczyk, Stanislaw J. ;
Sitaraman, Kalavathy ;
Young, Howard A. ;
Hughes, Stephen H. ;
Chatterjee, Deb K. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2011, 108 (41) :16998-17003
[44]  
Kishimoto TK, 2016, NAT NANOTECHNOL, V11, P890, DOI [10.1038/nnano.2016.135, 10.1038/NNANO.2016.135]
[45]   In vivo toxicity of cationic micelles and liposomes [J].
Knudsen, Kristina Bram ;
Northeved, Helle ;
Kumar, Pramod E. K. ;
Permin, Anders ;
Gjetting, Torben ;
Andresen, Thomas L. ;
Larsen, Steen ;
Wegener, Karen Malene ;
Lykkesfeldt, Jens ;
Jantzen, Kim ;
Loft, Steffen ;
Moller, Peter ;
Roursgaard, Martin .
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2015, 11 (02) :467-477
[46]   Transport of surface-modified nanoparticles through cell monolayers [J].
Koch, AM ;
Reynolds, F ;
Merkle, HR ;
Weissleder, R ;
Josephson, L .
CHEMBIOCHEM, 2005, 6 (02) :337-345
[47]   ANTHRAX TOXIN PROTECTIVE ANTIGEN - LOW-PH-INDUCED HYDROPHOBICITY AND CHANNEL FORMATION IN LIPOSOMES [J].
KOEHLER, TM ;
COLLIER, RJ .
MOLECULAR MICROBIOLOGY, 1991, 5 (06) :1501-1506
[48]  
KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420
[49]   A phenylalanine clamp catalyzes protein translocation through the anthrax toxin pore [J].
Krantz, BA ;
Melnyk, RA ;
Zhang, S ;
Juris, SJ ;
Lacy, DB ;
Wu, ZY ;
Finkelstein, A ;
Collier, RJ .
SCIENCE, 2005, 309 (5735) :777-781
[50]   Phase I trial of recombinant immunotoxin anti-Tac(Fv)PE38 (LMB-2) in patients with hematologic malignancies [J].
Kreitman, RJ ;
Wilson, WH ;
White, JD ;
Stetler-Stevenson, M ;
Jaffe, ES ;
Giardina, S ;
Waldmann, TA ;
Pastan, I .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (08) :1622-1636